Show simple item record

dc.contributor.authorCojocaru, E
dc.contributor.authorWilding, C
dc.contributor.authorEngelman, B
dc.contributor.authorHuang, P
dc.contributor.authorJones, RL
dc.date.accessioned2020-07-09T12:05:08Z
dc.date.issued2020-03-01
dc.identifier.citationCurrent Molecular Biology Reports, 2020, 6 (1), pp. 1 - 9
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3837
dc.identifier.eissn2198-6428
dc.identifier.doi10.1007/s40610-020-00126-z
dc.description.abstract<jats:title>Abstract</jats:title><jats:p>Chondrosarcomas are rare cancers of bone that arise from the malignant transformation of cells of chondrocytic lineage. They are known to be resistant to systemic cytotoxic chemotherapy and radiotherapy. The mainstay of management of localised disease is <jats:italic>en bloc</jats:italic> surgical resection with curative intent. Metastatic chondrosarcoma has a dismal prognosis, and to date, there are no proven effective systemic therapies in the advanced setting. Genomic studies have demonstrated that 50 to 80% of chondrosarcomas harbour a mutation in either the <jats:italic>IDH1</jats:italic> or <jats:italic>IDH2</jats:italic> gene. IDH inhibitors are currently under investigation in clinical trials, after showing promising results in phase 1 studies in <jats:italic>IDH</jats:italic> mutated cancers. In chondrosarcoma, <jats:italic>IDH</jats:italic> mutations represent an attractive target, however, early results with IDH inhibitors in <jats:italic>IDH</jats:italic> mutated chondrosarcoma are modest and the final results of ongoing trials are eagerly awaited.</jats:p>
dc.format.extent1 - 9
dc.languageeng
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleIs the IDH Mutation a Good Target for Chondrosarcoma Treatment?
dc.typeJournal Article
rioxxterms.versionofrecord10.1007/s40610-020-00126-z
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-03
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCurrent Molecular Biology Reports
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.publication-statusPublished
pubs.volume6
pubs.embargo.termsNot known
icr.researchteamMolecular and Systems Oncology
dc.contributor.icrauthorCojocaru, Elena
dc.contributor.icrauthorWilding, Christopher
dc.contributor.icrauthorHuang, Paul


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0